The delegation members from Germany and the U.K. pose for a photo during their visit to Shenzhen New Industries Biomedical Engineering Co. Ltd. (briefed as Snibe Co. Ltd.) in Pingshan District. Photos courtesy of the organizers 

On May 28, medical companies from Germany and the U.K., alongside Shenzhen-based biotech firms, research institutes, and investment organizations, convened at the China (Shenzhen)-Germany Biotech Industry Investment Cooperation Conference held in Pingshan District.

Held at the Greater Bay Area International Vaccine Innovation Center, the conference focused on industry trends, R&D, legal and regulatory frameworks, equity investment, and new opportunities for biotech cooperation between China and Germany.

The delegation members from Germany and the U.K. during their visit in Pingshan District.

Representatives from Pharma Deutschland, Klosterfrau Healthcare Group, IMSTec, Sanemus AG, Vivan Therapeutics, and Fine Treatment presented their core businesses, achievements, and investment intentions in China. They expressed strong confidence in Shenzhen’s investment environment and growth prospects, and signaled their willingness to collaborate with Shenzhen in R&D, clinical research, and market expansion.

Tang Song, deputy director of the Investment Promotion Agency of China’s Ministry of Commerce, emphasized that biotech is one of Shenzhen’s most distinctive and advantageous industries. He highlighted Pingshan District’s strengths in basic research, entrepreneurship, investment, the integration of industry and medicine, institutional innovation, and talent attraction.

The delegation members from Germany and the U.K. pose for a photo during their visit to Shenzhen Main Luck Pharmaceuticals Inc. in Pingshan District.

Representatives from Pingshan introduced the district’s industrial policies, facilities, and industrial spaces dedicated to the biopharmaceutical sector. Representatives from Shenzhen Stock Exchange’s V-Next platform, which connects global innovation resources with Chinese capital and markets, gave a briefing on its cross-border services.

The delegation also visited Pingshan companies such as Shenzhen New Industries Biomedical Engineering Co. Ltd. (briefed as Snibe Co. Ltd.), Shenzhen Main Luck Pharmaceuticals Inc., and AnLing Biomed (Shenzhen) Co. Ltd., as well as the Shenzhen Bay Laboratory Pingshan Translational Medicine Center. Impressed by Shenzhen’s latest biotech advancements, delegation members expressed interest in future visits and deeper exchanges.